SHANGHAI, China, Feb. 18 /Xinhua-PRNewswire/ -- Today, NovaSecta, Sundia Meditech and HD BioSciences announced their strategic alliance to provide drug discovery solutions for European pharmaceutical and biotech companies. This alliance brings together the high quality scientific capabilities of Sundia and HD BioSciences with NovaSecta's extensive client base and unique understanding of European mid-sized pharmaceutical and biotech companies.
To date, the rapidly-growing Chinese Discovery CRO phenomenon has been largely driven by global and US "Big Pharma" and "Big Biotech" companies -- both as consumers of CRO services and as sources of highly-experienced returnee scientists to China. European pharmaceutical and biotech companies now need to make use of the scientific skills, creative talent pool, flexible resourcing and cost-effectiveness that many global Big Pharmas already take for granted in China.
NovaSecta's business is centered on providing smaller to mid-sized pharmaceutical and biotech companies the scale advantages that Big Pharmas enjoy while allowing them to remain independent, fast and flexible. This alliance is therefore a natural step in NovaSecta's evolution as an R&D services company. "We selected Sundia Meditech and HD BioSciences as our alliance partners based on their professionalism and track record in repeatedly delivering drug discovery solutions to their US and multi-national clients. Combining the skills and demonstrated drug discovery track record of their scientific teams with the expertise of European drug discovery scientists will surely lead to faster and more efficient generation of high quality drug candidates" said Robert Thong and John Rountree, NovaSecta's co- founders and Managing Directors.
Sundia Meditech, United PharmaTech, and HD BioSciences entered into a
CRO Service Alliance in May 2007. In the following months, Sundia and
United merged into one company, a first successful merger of China's CRO
|SOURCE Sundia Meditech|
Copyright©2008 PR Newswire.
All rights reserved